Safety results indicate that desvenlafaxine treatment is generally safe and well tolerated findings were consistent with those for the SNRI class.
#DESVENLAFAXINE SUCCINATE ER REGISTRATION#
An integrated analysis of registration data from 9 randomized, double-blind, placebo-controlled, 8-week studies of desvenlafaxine (50 to 400 mg/d) for MDD demonstrated no evidence of greater efficacy with doses higher than 50 mg/d. Significant improvements compared with placebo were observed on the primary efficacy measure (17-item Hamilton Depression Rating Scale total score) and most secondary measures in 2 of 3 clinical trials. In addition, the search retrieved an article examining pooled data from 9 trials, including 50-mg data from 2 of the 3 retrieved trials.ĭata synthesis: Desvenlafaxine is the major active metabolite of the SNRI venlafaxine. The third of these studies included a post hoc pooled analysis of data from all 3 of these trials. Study selection: Three randomized, placebo- and/or active comparator-controlled, 8-week clinical trials reported the efficacy of desvenlafaxine 50 mg/d for the treatment of MDD. Keywords were desvenlafaxine, O– desmethylvenlafaxine, ODV, and 50 mg. Additionally, the article discusses clinical practice considerations and future directions in desvenlafaxine research.ĭata sources: Data relating to desvenlafaxine 50 mg/d were identified through searches of MEDLINE and publication databases of Pfizer for articles in English published before January 2009. This article summarizes data on the clinical pharmacology, efficacy, safety, and tolerability of desvenlafaxine (administered as desvenlafaxine succinate) for MDD with a focus on the 50-mg/d therapeutic dose. Objective: Desvenlafaxine is the third serotonin-norepinephrine reuptake inhibitor (SNRI) approved by the US Food and Drug Administration for major depressive disorder (MDD).
![desvenlafaxine succinate er desvenlafaxine succinate er](https://ars.els-cdn.com/content/image/3-s2.0-B978012820472600044X-f00044-06-9780128204726.jpg)
Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of Major Depressive Disorder: A Systematic Review of Clinical Trials